Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204
Marvel Biosciences Corp. , and its wholly owned subsidiary, Marvel Biotechnology Inc. , today reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel...
Mark Williams Emmanuel Planel Marvel Biotechnology Inc Regulation Services Provider Alberta Newsfile Corp Laval University
Source: marketscreener.com